PMID- 25255411
OWN - NLM
STAT- MEDLINE
DCOM- 20150203
LR  - 20220317
IS  - 2154-8331 (Print)
IS  - 2154-8331 (Linking)
VI  - 42
IP  - 3
DP  - 2014 Aug
TI  - Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of 
      type 2 diabetes.
PG  - 96-108
LID - 10.3810/hp.2014.08.1122 [doi]
AB  - The kidney plays a key role in glucose homeostasis and the pathophysiology of 
      type 2 diabetes mellitus (T2DM). Sodium glucose co-transporter 2 (SGLT2) 
      inhibitors are a new class of antihyperglycemic agents for the treatment of T2DM 
      with a novel insulin-independent mechanism of action that targets the kidney. The 
      SGLT2 inhibitors decrease renal glucose reabsorption, thereby increasing urinary 
      glucose excretion and lowering plasma glucose levels in patients with 
      hyperglycemia. SGLT2 inhibitor canagliflozin has demonstrated efficacy in 
      improving glycemic control and reducing body weight and blood pressure as 
      monotherapy or as add-on to other antihyperglycemic agents across a broad range 
      of patients with T2DM. Canagliflozin is generally well tolerated, with increased 
      incidences of specific adverse events that are related to the mechanism of SGLT2 
      inhibition. Findings suggest that canagliflozin is a useful treatment option for 
      patients with T2DM.
FAU - Brunton, Stephen
AU  - Brunton S
AD  - Executive Director, Primary Care Metabolic Group, Charlotte, NC.
FAU - Reid, Timothy S
AU  - Reid TS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Hosp Pract (1995)
JT  - Hospital practice (1995)
JID - 101268948
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Lipids)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiophenes)
RN  - 0SAC974Z85 (Canagliflozin)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - Blood Pressure/physiology
MH  - Body Weight
MH  - Canagliflozin
MH  - Clinical Trials, Phase III as Topic
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Therapy, Combination
MH  - Glucosides/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Kidney/metabolism
MH  - Lipids/blood
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Thiophenes/administration & dosage/adverse effects/*therapeutic use
EDAT- 2014/09/26 06:00
MHDA- 2015/02/04 06:00
CRDT- 2014/09/26 06:00
PHST- 2014/09/26 06:00 [entrez]
PHST- 2014/09/26 06:00 [pubmed]
PHST- 2015/02/04 06:00 [medline]
AID - 10.3810/hp.2014.08.1122 [doi]
PST - ppublish
SO  - Hosp Pract (1995). 2014 Aug;42(3):96-108. doi: 10.3810/hp.2014.08.1122.